Comparison of Two Forms of Loperamide–Simeticone and a Probiotic Yeast (Saccharomyces boulardii) in the Treatment of Acute Diarrhoea in Adults: A Randomised Non-Inferiority Clinical Trial

Abstract

BackgroundAcute diarrhoea is a frequent health problem in both travellers and residents that has a social and economic impact. This study compared the efficacy and tolerability of two loperamide–simeticone formulations and a Saccharomyces boulardii capsule as symptomatic treatment.MethodsThis was a prospective, randomised, single (investigator)-blind, three-arm, parallel group, non-inferiority clinical trial in adult subjects with acute diarrhoea at clinics in Mexico and India, with allocation to a loperamide–simeticone 2/125 mg caplet or chewable tablet (maximum eight in 48 h) or S. boulardii (250 mg twice daily for 5 days).Outcome MeasuresThe primary outcome measure was the number of unformed stools between 0 and 24 h following the initial dose of study medication (NUS 0–24). The secondary outcome measures were time to last unformed stool (TLUS), time to complete relief of diarrhoea (TCRD), time to complete relief of abdominal discomfort (TCRAD) and the subject’s evaluation of treatment effectiveness. Follow-up endpoints at 7 days were feeling of complete wellness; stool passed since final study visit; and continued or recurrent diarrhoea.SubjectsIn this study, 415 subjects were randomised to either a loperamide–simeticone caplet (n = 139), loperamide–simeticone chewable tablet (n = 139) or S. boulardii capsule (n = 137) and were included in the intention-to-treat analysis.ResultsWith regards to mean NUS 0–24, the loperamide–simeticone caplet was non-inferior to loperamide–simeticone tablets (3.4 vs. 3.3; one-sided 97.5 % confidence interval ≤0.5), with both significantly lower than S. boulardii (4.3; p < 0.001). The loperamide–simeticone groups had a shorter median TLUS [14.9 and 14.0 vs. 28.5 h (loperamide–simeticone caplet and chewable tablet groups, respectively, vs. S. boulardii); p < 0.001], TCRD (26.0 and 26.0 vs. 45.8 h; p < 0.001) and TCRAD (12.2 and 12.0 vs. 23.9 h; p < 0.005) than S. boulardii. Treatment effectiveness for overall illness, diarrhoea and abdominal discomfort relief was greater (p < 0.001) in the loperamide–simeticone groups than with S. boulardii. At 7-day follow-up most subjects reported passing stool at least once since the final study visit (loperamide–simeticone caplet 94.1 %, loperamide–simeticone chewable tablet 94.8 %, S. boulardii 97.0 %), did not experience continued or recurrent diarrhoea [loperamide–simeticone caplet 3.7 % (p < 0.03 vs. S. boulardii), loperamide–simeticone chewable tablet 3.7 %, S. boulardii 5.7 %] and felt completely well [loperamide–simeticone caplet 96.3 % (p < 0.02 vs. S. boulardii), loperamide–simeticone chewable tablet 96.3 % (p < 0.02 vs. S. boulardii), S. boulardii 88.6 %]. All treatments were well-tolerated with few adverse events.ConclusionsThe loperamide–simeticone caplet was non-inferior to the original loperamide–simeticone chewable tablet formulation; both formulations can be expected to demonstrate similar clinical efficacy in the relief of symptoms of acute diarrhoea. Both loperamide–simeticone formulations were superior to the S. boulardii c...

Open Clinical Trial on Using Nifuroxazide Compared to Probiotics in Treating Acute Diarrhoeas in Adults

“…However, after performing the stratification on children and adults age groups, there is statistically significant difference in pediatric population compared to adults where probiotics shown efficacy in subgroup of patients treated with antibiotics in eradication therapy of Helicobacter pylori. This study once again confirms the insufficiency of research results in adult population 14,15…”

Gut Microbiome–Brain Alliance: A Landscape View into Mental and Gastrointestinal Health and Disorders

“…They discovered that while the probiotic did help alleviate symptoms, it was inferior to loperamide/simeticone. 482 Clinical trial number NCT01099696 also had discouraging results researching the treatment of functional dyspepsia with probiotic Bif idobacterium infantis 35624. While previous studies showed promise in patients with IBS, 477 stress, anxiety Lacticaseibacillus paracasei Lpc-37 complete NCT04767997 474 sleep disorder undisclosed probiotic formulation recruiting NCT03601559 478 cognitive impairment Lactobacillus paracasei Lpc-37 complete NCT03615651 479 stress, cognition impairment Lactobacillus helveticus, Bifidobacterium longum, Lactiplantibacillus plantarum complete NCT05567653 473 stress Lactobacillus helveticus Rosell-52, Bif idobacterium longum Rosell-175 recruiting NCT03370458 480 stress Lactobacillus plantarum DR7 complete Bif idobacterium infantis 35624 did not show significant improvement in symptoms of abdominal discomfort and bloating in that study's participants.…”

“…They compared the treatment results of antigas/antidiarrheal drug combination loperamide/simeticone and probiotic yeast Saccharomyces boulardii . They discovered that while the probiotic did help alleviate symptoms, it was inferior to loperamide/simeticone . Clinical trial number NCT01099696 also had discouraging results researching the treatment of functional dyspepsia with probiotic Bifidobacterium infantis 35624.…”

Towards the Continuous Manufacturing of Liquisolid Tablets Containing Simethicone and Loperamide Hydrochloride with the Use of a Twin-Screw Granulator

“…Simethicone occurs as a hydrophobic, semiopaque, viscous fluid [11]. Loperamide is an effective antidiarrheal drug that is widely administered for the symptomatic treatment of various types of diarrhea [12,13]. The combination of loperamide and simethicone is used to treat acute diarrhea combined with abdominal distension and pain.…”